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ClIh qw. ,,,i,wir 
rcnn. pulmonary function te+ting. echocardiography and the 
alwnce of left :o rtghr shunting and clcvalcd Icft heart 
prcswre\ on cathctcriratmn. nccording to thl: protocol of the 
National Inxtitntc~ of Heahh Primary Pulmonary Hyperlen- 
\ton Rcgbtry 16). 
naseline ficmnd~namic measurements. Diagnostic right 
heart catheterization WI pcrformcd on all palicnlb after an 
overnight fa\l. All mcdtcation\. with the exceplion of dig- 
own tmd diuretic\. wcrc dixontinued for at least 2 weeks 
hcforc lhc wdy. Palwnt~ not receiving digoain bcpan treat- 
mcnt with rhea drug hefore hospital ndmibaion. Systemic and 
prtlmonary ttrtcry preawes and cardiac output by thermodi. 
lut~on technique were mcasurcd. with vt~lucs for pulmonary 
viwzttlar rc,ittancc and systemic vascular re*istance calcu. 
lt~red according to standard formulab. Placement of the 
EBI~EICI~ w+\ performed in the cardiac catheterization lab. 
oratory. The paticntr were transferred to the coronary citrc 
unit with a thermodilutiun flow-directed catheter in the 
pulmonary artery and a bmttll ttrterial cannula in the femural 
artcry for drug cr’alua~ton. Patients were allowed 3 IO 4 h In 
bccomc occlimtncd to the coronary care unit wrounding\. 
A minimum ofihrcc rccordine% 3U min aparl. were ohiaincd 
toestahlich hwline hcmodynamic vaiue~ before initiation of 
the drug study. 
Acute calcium channel hlockcr challenge. All ptlienls 
rcccived an inilinl challenge of a ~wt~en~~onal oral dose of 
nifcdiptne I20 mg. 42 patients1 or diltiazem 0% mg, 5 pa- 
rienlst. with hcmodynamic mearuremcnt~ made alter I h. 
Consecutive oral doses of either nifcdipinc or dihiazem were 
then administered hourly to the paricnts: until It a positive 
rcvonsr occurred ldefmed as tt dccreasc in both mean 
pulmonary artery prcsrnrc and pulmonary vascular rests- 
tance Gth no further decrease aRer one additional doset. 
?I the patienl experienced an adverse effect of the drug 
requiring III diacwtinuution. or 3) IO consecutive hourly 
dew were given. Fur purposes of thb study. 2tJ mg of 
nifedipmc and 60 ntg of diltiazem wcrc considered to be 
cquwelent oral doses. Nifedipine was rclccted ttnlebs the 
paticnl had a heart rate at rest >I00 bcatalmin. In patienls 
who had a favorahlo response. halfof the cumulative dose of 
drug deemed e&&e ww rhen readministcrcd every 6 IO 8 h 
(dcpcndina on Ihe duration of actionl over a 24-h period. 
Final hemodynamic rneesurcmcnts were made I h after the 
last dose. 
Characterization of the hemadynamic response. For pw 
pores of analysis of the effect of the drug challcngea. four 
types of responses were characterized. A “pressure rc. 
spender” was defined a$ a patient who had :I 20% reduction 
in rncsn pulmonary artery pressure. with a Gnthtr or grcaler 
reduction in calculated pulmonary vascular rcci~tance. A 
‘*rcsi%ancc responder” was a patient who had il reduclion of 
%20% in pulmonary vascular resistance hut of ~20% in 
mean pulmonary artery pressure. Patients who did “01 have 
a reduction of 2OR in either pulmonary artcry presserc or 
pulmonary vascttlar resistance were considered nonre- 
sponderb. Patients who were unable to tolerate more than a 
Gtgle dare uf the owl calcium blocker VW considered 4s a 
,eparate proup. 
Statistical analysis. Mean vatucs ? SD were computed 
for all variahlec measured. Comoarirons between control 
and treated statea were made bv wired Student’s r test. 
Difference\ hetwecn the cfTect nf’conventional and high 
doses of the drug were evaluated with McNcmar’s WSI. 
Compariwm between the rcbponses of edch ofthe different 
groups were mude with one-way analysis of variance. 
Results 
“Prew~re responders” (Pig. It. The baseline demo- 
Fraphic and hemodynamic chsracteristics and response IO 
calcium channel blockers of the patients arc noted in Table 
I, Fifteen patients were characterized as “pressure respond- 
er+..” As a proup. thcw patients had .I reducric,t in mean 
pulmonary awry prwure of 6.8 i 6% Ip = NS) and a I? * 
25% :cducliun in pulmonary vascular resistnnce Ip C 0.05) 
after the first dox of a calcium channel blocker. After 
maximal dose challenges. the reduction in mean pulmonnry 
artery preswrc wtts 36.2 - 8% tp c 0.01) and in pulmonary 
vascular rebirldncc ws 0. 5 2 i 7% tp < 0.01). This response 
was associated .with a 22.7 2 1% increase in cardiac outpur 
Ip < 0.011 and a IO.8 z II% reduction in mean systemic 
presswe tp C U.ttl L No bignilicant change in heart rate. right 
atria1 pressure or wedge pressure wns ohserved. 
Resbtance responders (Fig. 21. Nineteen patients were 
chardcterizcd as “resistance wponders.” In this group. the 
reduction in mean pulmonary arlcry pressure after the initial 
dose of calcium blocker was 5.7 % a% tp = NS) wherexthc 
reducrion in pulmonary vascular resi~ttancc wa, 21.8 5 IY% 
Ip < O.Illk Althuugh there was il significam reduction lranpe 
5.9% lo 12%: p < tI.USI in mean syxtcmic arterial pressure 
with rhe maximal doire. tno further +tiiivant reduction in 
pulmonary artery prw,[lre 110.6 r II%) or pulmonttry 
vascular reriwnce t25.2 5 12%) occurred 81 the maximal 
dose when values were compared wilh Ihow meawrcd 
during the first dose. This group alw maniie*ted a lY.i? 
increase in cardiac wtp! ‘p < 0.01 I and an I I .W reduction 
in mew systemic pressure tp < 0.05) with no significant 
change in heart rate. nghl alrial prewre or pulmonary 
capillary wedge pressure. The number of do% qurcd 10 
achieve maximal effecr% in the pressure and rewt.mcc 
responders was 6 ? 2. I (range 3 to 111, 
Nmresuonden. Ten palienls were conridered nunrc- 
we hmiiedLour te\ling’ to the r/n&-d& challenges com- 
monlv used bvolhcr invcsliealor\ 13.3.7l. we would rrol have 
identified the porenrial of high dew 10 caux a Ikrrge redw 
lion in pulmonary artcry pressure. II is presumed lhat these 
high dose\ arc ncedcd hecause of the high level of v:~wcorv 
striction wilhin rhe puhnonary arteries. It i\ also pwrihl: 
that the higher doles elicit other propertie\ of Ihc calcium 
chnnncl blockers lhal arc nol mediillcd by lhur iiclions on 
vol!age-dependent calcium channrls. such as modulation of 
the nucleoride Iran\porler. which could aRccl adenorinc 
uptake by crythrocyter IR). 
A Z!O% reduction of pulmonary vwcul~r reiiamce 
without substantral changes in pulmonary anery preswre 
was the most common response (40%). Parienl\ whh Ihl, 
response had an mcrease in cardiac output and a dccrcarc in 
pulmonary wscuIa resirlance. but not 10 Ihe magnitude of 
the pressure recpon\e group and not to the point where the 
pulmonary artery pwwre was significantly reduced. In Ihi\ 
croup the hirher doses of the u!cium hlockcr reruhed in 
iirrle. further-reduclion in pulmonary wcular resist;mcc 
from lhat achieved with the milial dews. Conxquenlly. we 
recommend that such paUerxa. if wealed with a udcium 
blocker on B long.term hai%. he given the lowc~t effective 
dose that i\ identified. Among the potential advew ~Kects of 
the calcium blockers are negahvc inolropic properlie< that 
could imparr righl ventricular performance and potenliully 
affect lone-term morhidhv ad rnorlalitv 19). 
Predicting the lypp of response. One of our more surpns. 
ing finding5 WBF our inabihly to predict Ihe type of re\ponre 
to drug testing o)n the bui, of a paliem‘r rympmms or 
baseline hemodynarmc status. It remains our hia\ that pa. 
lienfs who have had symptoms for longer perrod, of lime and 
who have more were hemodynamic changes arc le% likely 
w rc\pond 10 Ihe calcium channel blockers. Howcvcr. 
hecaurc we were un;rhle ro clearly dcwihc a clinical profile 
of a patienl who will not respond to drug challenge. we 
rcm;dn ohligawd 10 te\t all patients with primary pulmonary 
h!prrren\ion ID elucidate whether the drugs might he of 
ootential hemodvnamic benefit. 
Mechanism oire5ponses. The mea logtcal explanation for 
the different recpowe, to the calcium channel blockers is 
th;u they reprerem dift’erenr lev& of reverity of pulmonary 
VBIEU~K disc&e t IOI. Thw. preswe rewmders would 
cornwise rhrne oatienl~ whose pulmonary vascular bed has 
the &te~r po&ial fordilalion and who therefore probably 
have ICII advanced di%a% The preferential influence ofthe 
calcium hlocken on the mdmonarv vas~ularure in lhesc 
paen!\ wggcxt\ heightened vawular lone in the pulmonary 
bed (5.10.1 IL Paticnl\ chardclerixd as resisumce rerpond- 
err probably have more advanced pulmonary vawdar dis- 
cart. The calcium blockers permit these patientr to adjurt to 
an increased cardiac output without causing a change i? 
pulmonary ancry preswre. However. the level of vssodila- 
tton I\ inwfficiem to cause a Ggnificanl decrease in pulmo- 
nary awry prewre. Thw patients had comparable reduc- 
tmn~ in w\ternic vaxular resistance as well. suggesting that 
the calcium blockers were working nonprefer&ially. Pa- 
lwnts clarified as nonresponders probably have even more 
advanced pulmonary &ular d&se whh B fixed pulmo- 
nary varcular rcGs!ance. These patients exhihircd a reduc- 
tion only in systemic vascular resiswtce. 
Adverse effeels. Six percent of Ihe patients tested were 
unable lo tokrac more than a single dose of the calcium 
blocker. These palicnrb probably had advanced dlseasc 
avocialcd with %vere right ventricular dysfunction. The 
onset oi hypolemion in these patients was associated with 
an increase in right atria1 pressure and a reduction in cardiac 
output. Thu\ it probably represented a negative inotropic 
efiect on a dysfunctional right venrricle in Ihe setting of a 
pulmonary vasculilr hed that has fixed pulmonary vascular 
rc~rlance. These ohservalions underscore the need to pay 
strict allention lo all hemodynamic variables. not just sys- 
temic and mdmonary artery pres~urt. when lestine vasodi- 
lators in &en!\ &h pul&~ary hypertension. _ 
Indication for hemcdynmnic monlloring. Our experience 
alw dictate\ SKI! varodilalor drugs should be administered 
initially IO pcllicnt> with pulmonary hypertension only with 
direct hemcdynamic monhoring. Whhout it. the physician 
cannot know how 10 adjurt Ihe dose for the patient’s 
maximitl hcnelicial &cl or monhor while changcel suggest- 
ing adverse hemodynamic elTec& tha might prove cam- 
rlrophic. Although we had no mortality or scrwn~~ morbidily 
in amv of the oauems that WC tested. adverse etl’ectr of these 
drug; and dealhs have been previously reported t 12-141 and 
should not be Ignored. II iq our practice to either inhiate or 
mainlain digorin therapy in all ~atienis undergoing drug 
teuinp with the premix thal digoxin might counleracr neg_ 
alive inolropic effects of the calcium blockers. This hypoth- 

